"bcCategories","studyInvestigationalInterventions","studyDesignRationale","uuid:ID","id","name","label","description","studyEstimands","documentVersion"
"[]","[]","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","429015b0-e9eb-4084-bb15-115fce4df510","StudyDesign_1","Study Design 1","","The main design for the study","[]",""
